Exact Sciences Corporation (NASDAQ: EXAS ) stock is still in the negative from Jan. 1 levels with single-digit losses, which I believe could have been worse but was lifted by double-digit gains recorded during the past month. On Sept. 10, 2025, theGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the ma ...

Exact Sciences Corporation (NASDAQ: EXAS ) stock is still in the negative from Jan. 1 levels with single-digit losses, which I believe could have been worse but was lifted by double-digit gains recorded during the past month. On Sept. 10, 2025, theGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the ma ...

Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing actionable trading ideas and well-researched investment recommendations. His insights have been featured in reputable publications such as The Axis business magazine and Investment Quarterly ...

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) stock is enjoying double-digit gains this month, after rising slightly above 20%. During the COVID boom, the company thrived on large upfront payments and government contracts, driving peak revenues and visibility. Now, that waveGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statem ...

Stereotaxis, Inc. (NYSE: NYSE: STXS ) stock is having a good year and the past six months have been even more exciting with double-digit gains reaching as high as over 40%. The company has been faced with a disturbingly volatile revenue stream, 'Systems', which isGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital mar ...

Kura Oncology, Inc. (NASDAQ: KURA ) stock is having a good month and is now on double-digit gains, although still trading slightly above its 52-week lower range. I believe the market is responding to the fast-approaching U.S. Food andGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, G ...

Butterfly Network, Inc. (NYSE: BFLY ) last week announced the appointment of Victor Ku as Senior Vice President and Chief Technology Officer (CTO), a move I believe has all to do with the company's efforts to 'rectify' its financialGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gam ...

Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing actionable trading ideas and well-researched investment recommendations. His insights have been featured in reputable publications such as The Axis business magazine and Investment Quarterly ...

Genmab A/S ( GMAB ) stock is experiencing its best month so far with double-digit gains, and it appears to be the best so far this year. The growth might be coming from an excellent H1 2025Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing ac ...

Genmab A/S ( GMAB ) stock is experiencing its best month so far with double-digit gains, and it appears to be the best so far this year. The growth might be coming from an excellent H1 2025Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing ac ...